Holland Capital
Holland Capital provides venture, growth and buy-out capital to small and medium-sized businesses with growth ambitions in the Benelux and Germany. Its stated focus is Healthcare and Technology, with criteria including significant growth potential, a unique product or service, strong management and capital needs between EUR 500k and 20m.
What stands out about Holland Capital
Holland Capital’s stated investment parameters are Healthcare and Technology focus, headquarters in the Benelux or Germany, significant growth potential, a differentiated product or service, strong management and capital needs between EUR 500k and 20m. It states that both majority and minority stakes are possible and that it works actively with entrepreneurs on strategic development and operational improvements.[1][2][3][4][7]
What does Holland Capital invest in?
Holland Capital is the trading name of Holland Capital Management B.V., whose registered office and principal place of business are in Amsterdam, the Netherlands. The firm states that its investment organisation was founded in 1981 and has operated under the Holland Capital name since January 1, 2019.
Holland Capital invests in promising small and medium-sized businesses with growth ambitions in the Benelux and Germany, focusing on Healthcare and Technology. It provides venture, growth and buy-out capital and actively cooperates with entrepreneurs on strategic development and operational improvements.[1][2][3]
Holland Capital describes an investment model that combines venture, growth and buy-out capital with active cooperation with entrepreneurs. Its stated support includes strategic development and operational improvements.
The firm states that it invests through Growth & Buy-out and Venture & Growth segments and that both majority and minority stakes are possible.[3][5]
Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.
What should a business owner evaluate before considering a transaction with Holland Capital?
An owner evaluating Holland Capital can compare the stated criteria with the company’s sector, headquarters, growth profile, product or service differentiation, management team and capital needs. The stated parameters cover Healthcare and Technology businesses in the Benelux or Germany, with capital needs between EUR 500k and 20m.
The firm states that both majority and minority stakes are possible and presents an active approach involving strategic development and operational improvements. Owners should therefore clarify the proposed ownership percentage and governance rights, the applicable venture, growth or buy-out process, the fund making the investment, follow-on capital availability, valuation and rollover expectations, operating resources, and potential exit routes.[3][5]
What ownership percentage and governance rights would Holland Capital seek
Which fund would make the investment, and what is the remaining investment period of that fund
What companies does Holland Capital target?
Holland Capital states that its target companies should have significant growth potential, a unique product or service, committed and strong management, and capital needs between EUR 500k and 20m. The firm describes its target businesses as small and medium-sized companies with growth ambitions.
Holland Capital states that it currently has EUR 500m under management and has invested in more than 200 entrepreneurs in recent years.[3]
Healthcare is a stated focus, including healthcare services, medical devices, diagnostics and digital health. Technology coverage includes IT services, specialised consultancies, software, high-tech, agrifood tech, advanced equipment and energy transition.
Holland Capital’s 2024 review also identifies Agrifood-Tech as a focus area.[4]
Holland Capital’s stated investment geography is the Benelux and Germany. Its investment criteria specify that target companies should have headquarters in the Benelux or Germany.[3]
The firm’s public examples include portfolio-company acquisitions. Holland Capital announced that Kids Lodge acquired childcare provider Donkey on September 14, 2026, that Lopital acquired Culsana as a strategic add-on acquisition on June 15, 2026, and that Kids Lodge acquired Kinderparadijs Jansen & Jansen on April 28, 2026.
These announcements establish portfolio-company acquisition activity; the cited announcements do not disclose purchase price, valuation, financing terms or exact ownership percentage.[4]
Holland Capital’s official project archive identifies Sibi, KinderThuisZorg, EAE, HuisartsenHulp and Pluggerz as portfolio or recent investment entries dated March-May 2026.
Other publicly announced examples include Holland Capital’s announced investment in Blyott, which provides real-time medical-equipment tracking and AI-supported equipment-use insights for healthcare organisations, and its announced investment in German medical-data platform Honic, for which Holland Capital stated that it led the funding round.[6][8][9]
Recent official examples include Holland Capital’s portfolio or recent investment entry for KinderThuisZorg, dated March-May 2026; Holland Capital’s announcement on March 21, 2026 that Sibi secured an investment from Holland Capital and Oost NL; and the acquisitions by portfolio companies Kids Lodge and Lopital described above.
Holland Capital also announced on August 27, 2025 that portfolio company HealthConnected was acquired by software company Visma. Earlier announcements include Holland Capital’s announced investment in Blyott on September 13, 2024 and announced investment in Honic on December 19, 2023.[4][6][7][8][9]
What is not clear from Holland Capital's public investment criteria?
The cited official privacy statement identifies Holland Capital Management B.V. and its Chamber of Commerce number but does not state an AFM or DNB licence or registration number.
The cited official home page news entries for Donkey, Culsana, Kinderparadijs Jansen & Jansen, KinderThuisZorg and Sibi identify the transactions or investments but do not disclose purchase price, valuation, financing terms or exact ownership percentage.
The cited official HealthConnected announcement identifies Visma as the acquirer but does not disclose transaction value, consideration terms or Holland Capital’s exact ownership percentage before the sale.[1][4][7]
Questions to ask when evaluating Holland Capital as a buyer or investment partner
What ownership percentage and governance rights would Holland Capital seek?
Which fund would make the investment, and what is the remaining investment period of that fund?
How would Holland Capital distinguish its venture, growth and buy-out underwriting processes?
What follow-on capital could be available for acquisitions or international expansion?
Which portfolio-company executives, sector partners and operating resources would support the business?
What valuation ranges, leverage parameters and rollover expectations would apply?
Sources & research notes
- Official website / firm overview
- Official website / firm overview
- Investment strategy
- Industry / market focus
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.